Baxter InternationalBAXEarnings & Financial Report
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
Revenue
$2.7B
Gross Profit
$1.0B
Operating Profit
$155.0M
Net Profit
$140.0M
Gross Margin
38.3%
Operating Margin
5.7%
Net Margin
5.2%
YoY Growth
-27.2%
EPS
$0.27
Baxter International Q3 FY2024 Financial Summary
Baxter International reported revenue of $2.7B (down 27.2% YoY) for Q3 FY2024, with a net profit of $140.0M (down 94.4% YoY) (5.2% margin). Cost of goods sold was $1.7B, operating expenses totaled $878.0M.
Key Financial Metrics
| Total Revenue | $2.7B |
|---|---|
| Net Profit | $140.0M |
| Gross Margin | 38.3% |
| Operating Margin | 5.7% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
Baxter International Q3 FY2024 revenue of $2.7B breaks down across 6 segments, led by Discontinued Operations Disposed Of By Sale at $1.2B (42.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Discontinued Operations Disposed Of By Sale | $1.2B | 42.8% |
| Infusion Therapies And Technologies | $613.0M | 22.7% |
| Care And Connectivity Solutions | $335.0M | 12.4% |
| Pharmaceutical Compounding | $267.0M | 9.9% |
| Injectables And Anesthesia | $178.0M | 6.6% |
| Advanced Surgery | $149.0M | 5.5% |
Baxter International Revenue by Segment — Quarterly Trend
Baxter International revenue by segment across the last 4 reported quarters, showing how each business line (such as Discontinued Operations Disposed Of By Sale and Infusion Therapies And Technologies) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Infusion Therapies And Technologies | — | $543.0M | $555.0M | $554.0M |
| Care And Connectivity Solutions | — | — | $348.0M | $341.0M |
| Pharmaceutical Compounding | — | $316.0M | $299.0M | $280.0M |
| Injectables And Anesthesia | — | $190.0M | $177.0M | $187.0M |
Baxter International Annual Revenue by Year
Baxter International annual revenue history includes year-by-year totals (for example, 2025 revenue was $11.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $11.2B |
| 2024 | $10.6B |
| 2023 | $14.8B |
| 2022 | $15.1B |
Baxter International Quarterly Revenue & Net Profit History
Baxter International results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $2.7B | +3.0% | $-15.0M | -0.6% |
| Q4 FY2025 | $3.0B | +458.0% | $-1.1B | -37.9% |
| Q3 FY2025 | $2.8B | +5.0% | $-46.0M | -1.6% |
| Q2 FY2025 | $2.8B | -26.3% | $91.0M | 3.2% |
| Q1 FY2025 | $2.6B | -26.9% | $126.0M | 4.8% |
| Q4 FY2024 | $533.0M | -85.8% | $-512.0M | -96.1% |
| Q3 FY2024 | $2.7B | -27.2% | $140.0M | 5.2% |
| Q2 FY2024 | $3.8B | +2.8% | $-314.0M | -8.2% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.81B | $2.70B | $533.0M | $2.63B | $2.81B | $2.83B | $2.97B | $2.70B |
| YoY Growth | 2.8% | -27.2% | -85.8% | -26.9% | -26.3% | 5.0% | 458.0% | 3.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $26.31B | $26.68B | $25.78B | $21.30B | $21.05B | $21.07B | $20.05B | N/A |
| Liabilities | $18.60B | $18.73B | $18.76B | $14.25B | $13.75B | $13.85B | $13.95B | N/A |
| Equity | $7.64B | $7.87B | $6.96B | $7.08B | $7.32B | $7.24B | $6.13B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $115.0M | $253.0M | $488.0M | $-193.0M | $217.0M | $237.0M | $584.0M |